Universal Biosensors surges 60% on FDA approval for Class II device
Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical Laboratory Improvement Amendments Waiver approvals.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
REF | Bye bye Reverse Corp | 14/08/22 | 2 | 966 | |||
|
|||||||
REF | Shareholder meeting | 05/07/22 | 6 | 1.5K | |||
|
|||||||
REF | Half yearly report | 10/05/22 | 0 | 316 | |||
|
|||||||
REF | Unlisted public company | 03/02/22 | 4 | 1.3K | |||
|
|||||||
REF | Ann: Notice of Annual General Meeting/Proxy Form | 11:04 | 11 | 1.6K | |||
|
|||||||
REF | News: REF Reverse Corp Says Acknowledged ASX's Decision To Remove REF From Asx | 17/01/22 | 0 | 190 | |||
|
|||||||
REF | Ann: Market Update | 17/01/22 | 0 | 370 | |||
|
|||||||
REF | Ann: Removal from Official List | 17/01/22 | 1 | 515 | |||
|
See All Discussions